Home LiteratureArticle Details
PMID: 18598914 Published · ppublish English Journal Article Research Support, N.I.H., Intramural Review

Pandemic and seasonal influenza: therapeutic challenges.

Drug discovery today ·Vol. 13 ·No. 13-14 ·2008-07-00 ·Pages 590-5

Memoli MJ, Morens DM, Taubenberger JK

Abstract

Influenza A viruses cause significant morbidity and mortality annually, and the threat of a pandemic underscores the need for new therapeutic strategies. Here, we briefly discuss novel antiviral agents under investigation, the limitations of current antiviral therapy and stress the importance of secondary bacterial infections in seasonal and pandemic influenza. Additionally, the lack of new antibiotics available to treat increasingly drug resistant organisms such as methicillin-resistant Staphylococcus aureus, pneumococci, Acinetobacter, extended spectrum beta-lactamase producing gram negative bacteria and Clostridium difficile is highlighted as an important component of influenza treatment and pandemic preparedness. Addressing these problems will require a multidisciplinary approach, which includes the development of novel antivirals and new antibiotics, as well as a better understanding of the role secondary infections play on the morbidity and mortality of influenza infection.

MeSH Terms
Antiviral Agents/therapeutic use Cross Infection/complications,drug therapy,epidemiology Disease Outbreaks Humans Influenza, Human/complications,epidemiology,therapy Pharmacology, Clinical Seasons
Chemicals
Antiviral Agents
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Memoli Matthew J
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. memolim@niaid.nih.gov
Morens David M
Taubenberger Jeffery K
References (57)
57 references, click to expand
  1. Trends in antimicrobial drug development: implications for the future.
    Clin Infect Dis. 2004 May 1;38(9):1279-86 PMID: 15127341
  2. Mechanism of action of T-705 against influenza virus.
    Antimicrob Agents Chemother. 2005 Mar;49(3):981-6 PMID: 15728892
  3. Influenza-associated morbidity and mortality in young and middle-aged women.
    JAMA. 1999 Mar 10;281(10):901-7 PMID: 10078486
  4. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season.
    Emerg Infect Dis. 2006 Jun;12(6):894-9 PMID: 16707043
  5. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza--Louisiana and Georgia, December 2006-January 2007.
    MMWR Morb Mortal Wkly Rep. 2007 Apr 13;56(14):325-9 PMID: 17431376
  6. The 1918 influenza pandemic: insights for the 21st century.
    J Infect Dis. 2007 Apr 1;195(7):1018-28 PMID: 17330793
  7. Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84.
    Antimicrob Agents Chemother. 1985 Mar;27(3):309-13 PMID: 3888102
  8. Antiviral resistance in influenza viruses--implications for management and pandemic response.
    N Engl J Med. 2006 Feb 23;354(8):785-8 PMID: 16495389
  9. Studies on influenza in the pandemic of 1957-1958. II. Pulmonary complications of influenza.
    J Clin Invest. 1959 Jan;38(1 Part 2):213-65 PMID: 13620784
  10. Avian flu: isolation of drug-resistant H5N1 virus.
    Nature. 2005 Oct 20;437(7062):1108 PMID: 16228009
  11. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.
    Am J Infect Control. 2004 Dec;32(8):470-85 PMID: 15573054
  12. Statin protection against influenza and COPD mortality.
    Chest. 2007 Oct;132(4):1406; author reply 1406-7 PMID: 17934130
  13. Human influenza A (H5N1) cases, urban areas of People's Republic of China, 2005-2006.
    Emerg Infect Dis. 2007 Jul;13(7):1061-4 PMID: 18214180
  14. Recent anti-influenza strategies in multivalent sialyloligosaccharides and sialylmimetics approaches.
    Curr Med Chem. 2007;14(21):2304-13 PMID: 17896978
  15. Statins have no role in pulmonary disease mortality.
    Chest. 2007 Oct;132(4):1408; author reply 1408-9 PMID: 17934132
  16. Are we ready for pandemic influenza?
    Science. 2003 Nov 28;302(5650):1519-22 PMID: 14645836
  17. H5N1 outbreaks and enzootic influenza.
    Emerg Infect Dis. 2006 Jan;12(1):3-8 PMID: 16494709
  18. Protection against lethal influenza virus challenge by RNA interference in vivo.
    Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8682-6 PMID: 15173583
  19. Effective small interfering RNAs targeting matrix and nucleocapsid protein gene inhibit influenza A virus replication in cells and mice.
    Antiviral Res. 2007 Nov;76(2):186-93 PMID: 17719657
  20. Low pH gel intranasal sprays inactivate influenza viruses in vitro and protect ferrets against influenza infection.
    Respir Res. 2007 May 17;8:38 PMID: 17509128
  21. Oseltamivir resistance during treatment of influenza A (H5N1) infection.
    N Engl J Med. 2005 Dec 22;353(25):2667-72 PMID: 16371632
  22. Prevention and treatment of influenza.
    N Engl J Med. 2000 Dec 14;343(24):1778-87 PMID: 11114318
  23. Detecting human-to-human transmission of avian influenza A (H5N1).
    Emerg Infect Dis. 2007 Sep;13(9):1348-53 PMID: 18252106
  24. Antiviral therapy targeting viral polymerase.
    Curr Pharm Des. 2006;12(11):1339-55 PMID: 16611119
  25. Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells.
    J Virol. 2006 Dec;80(24):11960-7 PMID: 17005658
  26. Pandemic H5N1 influenza vaccine development: an update.
    Expert Rev Vaccines. 2008 Mar;7(2):241-7 PMID: 18324892
  27. Bacterial pneumonia during the Hong Kong influenza epidemic of 1968-1969.
    Arch Intern Med. 1971 Jun;127(6):1037-41 PMID: 5578560
  28. Re-emergence of fatal human influenza A subtype H5N1 disease.
    Lancet. 2004 Feb 21;363(9409):617-9 PMID: 14987888
  29. Global epidemiology of influenza: past and present.
    Annu Rev Med. 2000;51:407-21 PMID: 10774473
  30. H5N1 viruses and vaccines.
    PLoS Pathog. 2007 Mar;3(3):e40 PMID: 17335350
  31. 1918 Influenza: the mother of all pandemics.
    Emerg Infect Dis. 2006 Jan;12(1):15-22 PMID: 16494711
  32. Antiviral management of seasonal and pandemic influenza.
    J Infect Dis. 2006 Nov 1;194 Suppl 2:S119-26 PMID: 17163384
  33. Statins and influenza/COPD mortality.
    Chest. 2007 Oct;132(4):1407; author reply 1407-8 PMID: 17934131
  34. Methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia--a critical review.
    Semin Respir Infect. 1994 Sep;9(3):199-206 PMID: 7831542
  35. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus.
    Lancet Infect Dis. 2007 Jan;7(1):21-31 PMID: 17182341
  36. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern.
    Lancet. 2005 Oct 1;366(9492):1175-81 PMID: 16198766
  37. The pathology of influenza virus infections.
    Annu Rev Pathol. 2008;3:499-522 PMID: 18039138
  38. The next influenza pandemic: can it be predicted?
    JAMA. 2007 May 9;297(18):2025-7 PMID: 17488968
  39. Update on avian influenza A (H5N1) virus infection in humans.
    N Engl J Med. 2008 Jan 17;358(3):261-73 PMID: 18199865
  40. Confronting potential influenza A (H5N1) pandemic with better vaccines.
    Emerg Infect Dis. 2007 Oct;13(10):1512-8 PMID: 18258000
  41. The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance.
    Mol Biol Evol. 2007 Aug;24(8):1811-20 PMID: 17522084
  42. The global impact of influenza on morbidity and mortality.
    Vaccine. 1999 Jul 30;17 Suppl 1:S3-10 PMID: 10471173
  43. Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model.
    Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):12121-6 PMID: 16880383
  44. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.
    JAMA. 2000 Feb 23;283(8):1016-24 PMID: 10697061
  45. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide.
    J Infect Dis. 2007 Jul 15;196(2):249-57 PMID: 17570112
  46. Strategies for mitigating an influenza pandemic.
    Nature. 2006 Jul 27;442(7101):448-52 PMID: 16642006
  47. Influenza update 2007-2008: vaccine advances, pandemic preparation.
    Cleve Clin J Med. 2007 Dec;74(12):889-94 PMID: 18183839
  48. Emerging vaccines for influenza.
    Expert Opin Emerg Drugs. 2008 Mar;13(1):21-40 PMID: 18321146
  49. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection.
    J Virol. 1988 May;62(5):1508-12 PMID: 3282079
  50. The active sites of the influenza cap-dependent endonuclease are on different polymerase subunits.
    EMBO J. 2001 Apr 17;20(8):2078-86 PMID: 11296240
  51. In vitro and in vivo activities of anti-influenza virus compound T-705.
    Antimicrob Agents Chemother. 2002 Apr;46(4):977-81 PMID: 11897578
  52. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes.
    Clin Infect Dis. 2005 Jan 1;40(1):100-7 PMID: 15614698
  53. Resistant influenza A viruses in children treated with oseltamivir: descriptive study.
    Lancet. 2004 Aug 28-Sep 3;364(9436):759-65 PMID: 15337401
  54. H5N1 influenza--continuing evolution and spread.
    N Engl J Med. 2006 Nov 23;355(21):2174-7 PMID: 17124014
  55. Mortality associated with influenza and respiratory syncytial virus in the United States.
    JAMA. 2003 Jan 8;289(2):179-86 PMID: 12517228
  56. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic.
    Bull Hist Med. 2002 Spring;76(1):105-15 PMID: 11875246
  57. Probable person-to-person transmission of avian influenza A (H5N1).
    N Engl J Med. 2005 Jan 27;352(4):333-40 PMID: 15668219
Article Info
Journal
Drug discovery today
Abbr.
Drug Discov Today
ISSN
1359-6446
DOI
10.1016/j.drudis.2008.03.024
Email
memolim@niaid.nih.gov
Published
2008-07-00
Epub
2008-00-15
Pages
590-5
Language
English
Region
England
NLM ID
9604391
PMCID
PMC2556034
Subset
IM
Grants
Intramural NIH HHS · Z01 AI000995-01 · United States
Intramural NIH HHS · Z99 AI999999 · United States
External Links
PubMed source DOI: 10.1016/j.drudis.2008.03.024 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2